Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?
- 11 May 2021
- journal article
- editorial
- Published by Elsevier in Metabolism
- Vol. 121, 154796
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementMetabolism, 2017
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic reviewMetabolism, 2016
- Epidemiology and natural history of non-alcoholic fatty liver diseaseMetabolism, 2016
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 studyThe Lancet, 2016
- Nonalcoholic fatty liver disease and statinsMetabolism, 2015
- Statin use and non-alcoholic steatohepatitis in at risk individualsJournal of Hepatology, 2015
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levelsInternational Journal of Cardiology, 2013
- Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysisThe Lancet, 2010